Citations

Clear

554 citation(s) found for "Li, Gerald".

Anaphylactoid Reaction to Intravenous Contrast in Patient with Systemic Mastocytosis
Volcheck, Gerald W., Weingarten, Toby N. , Šprung, Juraj

Mayo Clinic

Anaesthesia and Intensive Care | January 16, 2019 | Volume: 37 | Issue: 4 | Pages: 646-649

10.1177/0310057x0903700415 | PMID 19681427 Get It

Systemic mastocytosis is a rare disorder characterised by tissue infiltration of morphologically abnormal mast cells and has been associated with severe anaphylactoid reactions during general anaesthesia. We report the case of a 43-year-old woman who developed a severe anaphylactoid reaction to iodinated contrast media. Persistently elevated serum tryptase levels led to further evaluation and the eventual diagnosis of systemic mastocytosis. This case highlights the importance of repeated measurements of serum tryptase levels following severe anaphylactoid reactions. The anaesthetist should also be aware of the propensity of these patients to develop severe anaphylactoid reactions during general anaesthesia and use treatment strategies to minimise this risk.
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Ramchandren, Radhakrishnan , Advani, Ranjana H. , Ansell, Stephen M. , Bartlett, Nancy L. , Chen, Robert , Connors, Joseph M. , Feldman, Tatyana , Forero‐Torres, Andres , Friedberg, Jonathan W. , Gopal, Ajay K. , Younes, Anas , Engley, Gerald, Manley, Thomas, Fenton, Keenan , Straus, David J. , Gordon, Leo I , Connors, Joseph M , Bartlett, Nancy L , Advani, Ranjana H , Gopal, Ajay , Gordon, Leo I. , Kuruvilla, John , Savage, Kerry J.

Mayo Clinic

Clinical Cancer Research | January 7, 2019 | Volume: 25 | Issue: 6 | Pages: 1718-1726

10.1158/1078-0432.ccr-18-2435 | PMID 30617130 Get It

Abstract Purpose: To evaluate safety and efficacy outcomes for subjects on the ECHELON-1 study treated in North America (NA). Patients and Methods: ECHELON-1 is a global, open-label, randomized phase III study comparing doxorubicin, vinblastine, and dacarbazine in combination with brentuximab vedotin (A+AVD) versus ABVD (AVD + bleomycin) as first-line therapy in subjects with stage III or IV classical Hodgkin lymphoma (cHL; NCT01712490). Subjects were randomized 1:1 to receive A+AVD or ABVD intravenously on days 1 and 15 of each 28-day cycle for up to 6 cycles. Results: The NA subgroup consisted of 497 subjects in the A+AVD (n = 250) and ABVD (n = 247) arms. Similar to the primary analysis based on the intent-to-treat population, the primary endpoint [modified progression-free survival (PFS) per independent review] demonstrated an improvement among subjects who received A+AVD compared with ABVD (HR = 0.60; P = 0.012). For PFS, the risk of progression or death was also reduced (HR = 0.50; P = 0.002). Subsequent anticancer therapies were lower in the A+AVD arm. Grade 3 or 4 adverse events (AEs) were more common, but there were fewer study discontinuations due to AEs in the A+AVD arm as compared with ABVD. Noted differences between arms included higher rates of febrile neutropenia (20% vs. 9%) and peripheral neuropathy (80% vs. 56%), but lower rates of pulmonary toxicity (3% vs. 10%) in subjects treated with A+AVD versus ABVD. Conclusions: The efficacy benefit and manageable toxicity profile observed in the NA subgroup of ECHELON-1 support A+AVD as a frontline treatment option for patients with stage III or IV cHL.
P1264Cardioprotective effects of a novel designer C-type natriuretic peptide-based therapeutic, C53, for the prevention of post-myocardial infarction heart failure
Dzhoyashvili, Nina , CHEN, YING‐SHREN, Harders, Gerald E., Burnett, John C. , Sangaralingham, S. Jeson , Ichiki, Tomoko , Sangaralingham, S. Jeson

Mayo Clinic

European Heart Journal | December 10, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy565.p1264 Get It

Models of Peer Support to Remediate Post-Intensive Care Syndrome: A Report Developed by the Society of Critical Care Medicine Thrive International Peer Support Collaborative*
McPeake, Joanne , Hirshberg, Eliotte L. , Christie, LeeAnn M., Drumright, Kelly, Hough, Catherine L. , Meyer, Joel , Wade, Dorothy , Andrews, Adair, Bakhru, Rita N. , Bates, Samantha , Barwise, John, Beesley, Sarah J. , Boehm, Leanne M. , Brown, Sheryl, Clay, Alison S. , Firshman, Penelope , Greenberg, Steven B. , Harris, Wendy, Hope, Aluko A. , Hopkins, Ramona O., Howell, David C., Jackson, James C. , Johnson, Annie, Kross, Erin K. , Lamas, Daniela, MacLeod-Smith, Belinda, Mandel, Ruth, Marshall, John C., Nackino, Megan, Quasim, Tara , Sevin, Carla M. , Slack, Andrew, Spurr, Rachel, Still, Mary, Thompson, Carol, Weinhouse, Gerald L., Wilcox, M. Elizabeth , Iwashyna, Theodore J. , Haines, Kimberley , Bastarache, Julie A. , Hill, Christopher, Hodgson, Carol Lynette , Holdsworth, Clare, Howell, David C. J., Janssen, Anna, Mikkelsen, Mark E.

Mayo Clinic

Critical Care Medicine | November 13, 2018 | Volume: 47 | Issue: 1 | Pages: e21-e27

10.1097/ccm.0000000000003497 | PMID 30422863 Get It

Objectives: Patients and caregivers can experience a range of physical, psychologic, and cognitive problems following critical care discharge. The use of peer support has been proposed as an innovative support mechanism. Design: We sought to identify technical, safety, and procedural aspects of existing operational models of peer support, among the Society of Critical Care Medicine Thrive Peer Support Collaborative. We also sought to categorize key distinctions between these models and elucidate barriers and facilitators to implementation. Subjects and Setting: Seventeen Thrive sites from the United States, United Kingdom, and Australia were represented by a range of healthcare professionals. Measurements and Main Results: Via an iterative process of in-person and email/conference calls, members of the Collaborative defined the key areas on which peer support models could be defined and compared, collected detailed self-reports from all sites, reviewed the information, and identified clusters of models. Barriers and challenges to implementation of peer support models were also documented. Within the Thrive Collaborative, six general models of peer support were identified: community based, psychologist-led outpatient, models-based within ICU follow-up clinics, online, groups based within ICU, and peer mentor models. The most common barriers to implementation were recruitment to groups, personnel input and training, sustainability and funding, risk management, and measuring success. Conclusions: A number of different models of peer support are currently being developed to help patients and families recover and grow in the postcritical care setting.
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients
Fetterly, Gerald, Pitzonka, Laura, Whitworth, Amy, LeVea, Charles , Wilton, John H., Mantione, Krystin , Schihl, Sarah A. , Dy, Grace K. , Iyer, Renuka , Brady, William E., Straubinger, Robert M. , Adjei, Alex A. , Ma, Wen Wee, Wee, Wen , Xie, Hao , Boland, Patrick M. , Tan, Wei

Mayo Clinic

American Journal of Clinical Oncology | November 8, 2018 | Volume: 42 | Issue: 2 | Pages: 184-189

10.1097/coc.0000000000000492 | PMID 30418178 Get It

Objectives: Preclinical studies demonstrated antitumor activity of dovitinib in pancreatic cancer models. This phase Ib study aimed to determine the maximum tolerated dose (MTD) of dovitinib in combination with gemcitabine and capecitabine and to characterize the safety and pharmacokinetic profile in patients with advanced pancreatic and biliary tract cancers and solid malignancies. Materials and Methods: Patients received gemcitabine 1000 mg/m² intravenously on days 1 and 8, capecitabine 1300 mg/m² oral daily from day 1 to 14, and dovitinib oral daily 5 days on and 2 days off, every 21-day cycle. The standard 3+3 dose escalation design was utilized and the study expanded to treat an additional 20 advanced pancreatic and biliary tract cancers patients at MTD. Results: A total of 29 patients were enrolled. One patient experienced dose-limiting grade 3 colitis. Two patients developed clinically significant neuropathy after the first cycle requiring dose reduction. The MTD was not reached and dovitinib 300 mg was declared the recommended dose for expansion. The most frequent grade 2 or worse adverse events were fatigue (45%), neutropenia (41%), thrombocytopenia (34%), anemia (24%), nausea (24%), and palmer-plantar erythrodysaesthesia syndrome (21%). Partial responses were observed in 5 patients. Pharmacokinetic studies showed no drug-drug interaction between dovitinib, capecitabine and gemcitabine. Fibroblast growth factor 23 plasma level increased in 4 of 5 patients during the first cycle of treatment. Conclusions: Dovitinib 300 mg daily is the recommended dose when combined with gemcitabine and capecitabine, achieving clinically relevant plasma concentrations. The study combination demonstrated encouraging efficacy signals in advanced pancreatic cancer.
Prediction of Arteriovenous Fistula Clinical Maturation from Postoperative Ultrasound Measurements: Findings from the Hemodialysis Fistula Maturation Study
Robbin, Michelle L. , Greene, Tom , Allon, Michael , Dember, Laura M. , Imrey, Peter B. , Cheung, Alfred K. , Kaufman, James S. , Radeva, Milena , Shiu, Yan-Ting , Vazquez, Miguel A. , Umphrey, Heidi , Alexander, Lauren F. , Abts, C., Beck, Gerald J. , Kusek, John W., Feldman, Harold I. , Group, the Hemodialysis Fistula Maturation Study, Alexander, Lauren, Alexander, Lauren F , Greene, Tom , Himmelfarb, Jonathan , Huber, Thomas S. , Roy‐Chaudhury, Prabir , Group, the Hemodialysis Fistula Maturation Study

Mayo Clinic

Journal of the American Society of Nephrology | October 11, 2018 | Volume: 29 | Issue: 11 | Pages: 2735-2744

10.1681/asn.2017111225 | PMID 30309898 Get It

Background The utility of early postoperative ultrasound measurements in predicting arteriovenous fistula (AVF) clinical maturation is uncertain. Methods We investigated the relationships of ultrasound parameters with AVF clinical maturation in newly created AVF, measured at 1 day and 2 and 6 weeks, in 602 participants of a multicenter, observational cohort study. A backward elimination algorithm identified ultrasound measurements that independently predicted unassisted and overall AVF maturation. Candidate variables included AVF blood flow, diameter, and depth, upper arm arterial diameter, presence of stenosis, presence of accessory veins, seven case-mix factors (age, sex, black race, AVF location, diabetes, dialysis status, and body mass index), and clinical center. We evaluated the accuracy of the resulting models for clinical prediction. Results At each ultrasound measurement time, AVF blood flow, diameter, and depth each predicted in a statistically significant manner both unassisted and overall clinical maturation. Moreover, neither the remaining ultrasound parameters nor case-mix factors were associated with clinical AVF maturation after accounting for blood flow, diameter, and depth, although maturation probabilities differed among clinical centers before and after accounting for these parameters. The crossvalidated area under the receiver operating characteristic curve for models constructed using these three ultrasound parameters was 0.69, 0.74, and 0.79 at 1 day and 2 and 6 weeks, respectively, for unassisted AVF clinical maturation and 0.69, 0.71, and 0.76, respectively, for overall AVF maturation. Conclusions AVF blood flow, diameter, and depth moderately predicted unassisted and overall AVF clinical maturation. The other factors considered did not further improve AVF maturation prediction.
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Inohara, Taku , Kim, Sunghee , Pieper, Karen S. , Blanco, Rosalia , Ezekowitz, Michael D. , Kowey, Peter R. , Reiffel, James A. , Mahaffey, Kenneth W. , Singer, Daniel E. , Piccini, Jonathan P. , Steinberg, Benjamin A , Allen, Larry A. , Fonarow, Gregg C. , Gersh, Bernard J. , Naccarelli, Gerald V. , Chan, Paul S. , Freeman, James V. , Steinberg, Benjamin A. , Peterson, Eric D.

Mayo Clinic

Heart | September 18, 2018 | Volume: 105 | Issue: 5 | Pages: 370-377

10.1136/heartjnl-2018-313642 | PMID 30228248 Get It

Objective The association with B-type natriuretic peptide (BNP), disease progression and outcomes in patients with atrial fibrillation (AF) has not been thoroughly investigated. Methods We evaluated the association between BNP levels and outcomes, including AF progression, composite outcome of major adverse cardiovascular or neurological events (MACNE) and major bleeding, via pooled logistic regression and Cox frailty models in Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II registry. AF progression was defined as either paroxysmal becoming persistent or permanent, or persistent becoming permanent at any follow-up. Results Among 13 375 patients with AF, 2797 with BNP values at baseline (median age (IQR), 72.0 (63.0–80.0) years; 43.0% women; median BNP, 238 (102–502) ng/L; 42.3% prior heart failure) were included in the models evaluating the association between BNP levels and MACNE or major bleeding. Of these, 1282 patients with paroxysmal or persistent AF at baseline were analysed in AF progression model. The likelihood of AF progression (adjusted OR, 1.11 for every 100 ng/mL; 95% CI 1.03 to 1.19) and MACNE (adjusted HR, 1.11 for every doubling in BNP values; 95% CI 1.01 to 1.22) increased with BNP concentration, while the elevated BNP values were not associated with increased risks of major bleeding. BNP values improved the risk prediction of AF progression and MACNE when added to conventional risk estimates. Conclusions BNP levels are associated with increased risk of AF progression and cardiovascular outcomes in patients with AF. Further studies are required to assess whether biomarker-based risk stratification improves patient outcomes. Clinical trial registration NCT01701817 .
Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low‐ and middle‐income countries
Roth, Daniel , Aloia, John F. , Bergeron, Gilles, Brown, Kenneth H. , Calvo, Mona S. , Combs, Gerald F., De‐Regil, Luz Maria , Jones, Kerry S. , Kapner, Hallie, Martineau, Adrian R. , Schleicher, Rosemary L. , Thacher, Tom D. , Whiting, Susan J. , Thacher, Thomas D , Abrams, Steven A. , Bourassa, Megan W. , Cashman, Kevin D. , Jefferds, Maria Elena , Neufeld, Lynnette Marie

Mayo Clinic

Annals of the New York Academy of Sciences | September 18, 2018 | Volume: 1430 | Issue: 1 | Pages: 44-79

10.1111/nyas.13968 | PMID 30225965 Get It

Abstract Vitamin D is an essential nutrient for bone health and may influence the risks of respiratory illness, adverse pregnancy outcomes, and chronic diseases of adulthood. Because many countries have a relatively low supply of foods rich in vitamin D and inadequate exposure to natural ultraviolet B (UVB) radiation from sunlight, an important proportion of the global population is at risk of vitamin D deficiency. There is general agreement that the minimum serum/plasma 25‐hydroxyvitamin D concentration (25(OH)D) that protects against vitamin D deficiency–related bone disease is approximately 30 nmol/L; therefore, this threshold is suitable to define vitamin D deficiency in population surveys. However, efforts to assess the vitamin D status of populations in low‐ and middle‐income countries have been hampered by limited availability of population‐representative 25(OH)D data, particularly among population subgroups most vulnerable to the skeletal and potential extraskeletal consequences of low vitamin D status, namely exclusively breastfed infants, children, adolescents, pregnant and lactating women, and the elderly. In the absence of 25(OH)D data, identification of communities that would benefit from public health interventions to improve vitamin D status may require proxy indicators of the population risk of vitamin D deficiency, such as the prevalence of rickets or metrics of usual UVB exposure. If a high prevalence of vitamin D deficiency is identified (>20% prevalence of 25(OH)D < 30 nmol/L) or the risk for vitamin D deficiency is determined to be high based on proxy indicators (e.g., prevalence of rickets >1%), food fortification and/or targeted vitamin D supplementation policies can be implemented to reduce the burden of vitamin D deficiency–related conditions in vulnerable populations.
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Washam, Jeffrey B. , Holmes, DaJuanicia N. , Thomas, Laine , Mahaffey, Kenneth W. , Kowey, Peter R. , Ansell, Jack , Go, Alan S. , Reiffel, James A. , Singer, Daniel E. , Blanco, Rosalia , Piccini, Jonathan P. , Pokorney, Sean D. , Hylek, Elaine M. , Fonarow, Gregg C. , Gersh, Bernard J. , Freeman, James V. , Naccarelli, Gerald V. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | September 17, 2018 | Volume: 7 | Issue: 18 | Pages: No page available

10.1161/jaha.118.008928 | PMID 30371218 Get It

Background Chronic kidney disease ( CKD ) is a common comorbidity in patients with atrial fibrillation. The presence of CKD complicates drug selection for stroke prevention and rhythm control. Methods and Results Patients enrolled in ORBIT AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) with baseline renal function and follow‐up data were included (N=9019). CKD was defined as an estimated creatinine clearance <60 mL /min. Patient characteristics were compared by CKD status, and Cox proportional hazards modeling was used to examine the association between oral anticoagulant ( OAC ) use and outcomes and antiarrhythmic drug use and outcomes stratified by CKD stages. At enrollment, 3490 (39%) patients had an estimated creatinine clearance <60 mL /min. Patients with CKD were older and had higher CHA 2 DS 2 VAS c and Anticoagulant and Risk Factors in Atrial Fibrillation (ATRIA) scores. A rhythm control strategy was selected less frequently in patients with CKD , while OAC use was lower among Stage IV and V CKD patients. After adjustment, no significant interaction was noted for OAC and CKD on all‐cause mortality ( P =0.5442) or cardiovascular death ( P =0.1233), although a trend for increased major bleeding ( P =0.0608) and stroke, systemic embolism or transient ischemic attack ( P =0.0671) was observed. No interaction was noted for antiarrhythmic drug use and CKD status on all‐cause mortality ( P =0.9706), or stroke, systemic embolism or transient ischemic attack ( P =0.4218). Conclusions Patients with atrial fibrillation and CKD are less likely to be treated with rhythm control. Patients with advanced CKD are less likely to receive OAC . Finally, outcomes with OAC in patients with advanced CKD may be materially different with higher rates of both bleeding and stroke.